As in the previous results for IgA AZA prevalence, the CD patients also showed a higher IgA AGA prevalence, which was significantly different to the observed prevalence in the IBS patients (64.9 % CD vs. 17.7 % IBS; p < 0.0001) and the HCs (64.9% CD group vs. 12.3% HC group; p < 0.0001). Here, CD79A is linked to irritable bowel syndrome.